Effector Therapeutics' Phase 2 KICKSTART trial results show no significant progression-free survival benefit for tomivosertib combined with pembrolizumab in NSCLC patients with high PD-L1.
Effector Therapeutics' Phase 2 KICKSTART trial results show that tomivosertib in combination with pembrolizumab did not meet the prespecified threshold for progression-free survival in non-small cell lung cancer (NSCLC) patients with PD-L1 ≥50%. The median PFS was 13.0 weeks in the tomivosertib arm and 11.7 weeks in the placebo arm. The combination also had a higher incidence of Grade 3 or higher treatment-emergent adverse events (67% vs 37%).
April 04, 2024
4 Articles